4-吡啶磺酰氯N-氧化物 | 98136-58-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 4-吡啶磺酰氯N-氧化物
• 英文名称: 4-pyridinesulfonyl chloride N-oxide
• 英文别名: Pyridin-N-oxid-sulfonsaeure-(4)-chlorid；1-Oxidopyridin-1-ium-4-sulfonyl chloride
• CAS: 98136-58-4
• 化学式: C₅H₄ClNO₃S
• 分子量: 193.611
• InChiKey: MKRTXRCNPIDUBV-UHFFFAOYSA-N

物化性质

• 沸点：
  425.4±18.0 °C(Predicted)
• 密度：
  1.58±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  68
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-吡啶磺酰氯N-氧化物 在 氢气 、 镍 、 lithium diisopropyl amide 作用下， 以 甲醇 、 氯仿 为溶剂， 反应 12.5h， 生成 4-(piperidinosulfonyl)pyridine-3-carboxylic acid
  参考文献：
  名称：

  Regioselective functionalization of pyridinesulfonic acids. Ortho-lithiation of tertiary 2- and 4-pyridinesulfonamides

  摘要：

  DOI：

  10.1021/jo00382a029
• 作为产物：
  描述：

  4-巯基吡啶N-氧化物 在 盐酸 、 氯 作用下， 生成 4-吡啶磺酰氯N-氧化物
  参考文献：
  名称：

  Regioselective functionalization of pyridinesulfonic acids. Ortho-lithiation of tertiary 2- and 4-pyridinesulfonamides

  摘要：

  DOI：

  10.1021/jo00382a029

文献信息

• Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
  申请人：——

  公开号：US20020193312A1

  公开（公告）日：2002-12-19

  Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

  本发明涉及一些能够结合VLA-4的化合物。其中某些化合物还能够抑制白细胞粘附，特别是VLA-4介导的白细胞粘附。这些化合物对哺乳动物患者（例如人类）的炎症性疾病治疗非常有用，例如哮喘、阿尔茨海默病、动脉硬化、艾滋病痴呆、糖尿病、炎症性肠病、类风湿性关节炎、组织移植、肿瘤转移和心肌缺血等。这些化合物也可以用于治疗炎症性脑部疾病，例如多发性硬化症。
• Steroid sparing agents and methods of using same
  申请人：Lieberburg Ivan

  公开号：US20060004019A1

  公开（公告）日：2006-01-05

  This invention relates generally to methods of treatment of inflammatory bowel diseases (IBD), asthma, multiple schlerosis (MS), rheumatoid arthritis (RA), graft vs. host disease (GVHD), host vs. graft disease, and various spondyloarthropathies, comprising administering a steroid sparing immunoglobulin or small molecule composition to a patient in need thereof. The invention also relates generally to combination therapies for the treatment of these conditions.

  本发明涉及治疗炎症性肠病(IBD)、哮喘、多发性硬化症(MS)、类风湿性关节炎(RA)、移植物抗宿主病(GVHD)、宿主抗移植物病以及各种脊柱关节病的方法，包括向需要治疗的患者投予一种节省类固醇的免疫球蛋白或小分子组合物。本发明还涉及治疗这些疾病的联合疗法。
• Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
  申请人：Karlik J. Stephen

  公开号：US20050215565A1

  公开（公告）日：2005-09-29

  The application provides for methods and compositions for inhibiting demyelination, promoting remyelination and/or treating paralysis in a subject in need thereof. Preferably, such compositions include immunoglobulins (e.g., antibodies, antibody fragments, and recombinantly produced antibodies or fragments), polypeptides (e.g., soluble forms of the ligand proteins for integrins) and small molecules, which when administered in an effective amount inhibits demyelination and/or promotes remyelination in a patient. The compositions and methods described herein can also utilize other anti-inflammatory agents used to palliate conditions and diseases associated with demyelination.

  该应用程序提供了用于抑制脱髓鞘、促进再髓鞘化和/或治疗需要的主体的瘫痪的方法和组合物。最好的情况是，这些组合物包括免疫球蛋白（例如，抗体、抗体片段和重组产生的抗体或片段）、多肽（例如，整合素配体蛋白的可溶性形式）和小分子，当以有效剂量在患者中施用时，可抑制脱髓鞘和/或促进再髓鞘化。本文描述的组合物和方法还可以利用其他抗炎药物来缓解与脱髓鞘相关的病症和疾病。
• Methods and compositions for treating rheumatoid arthritis
  申请人：Yednock A. Theodore

  公开号：US20050065192A1

  公开（公告）日：2005-03-24

  This application relates to methods and compositions for treating rheumatoid arthritis by administering a combination therapy comprising methotrexate and an antibody to alpha-4 integrin or an immunologically active antigen binding fragment in therapeutically effective amounts. The application also relates generally to methods and compositions for treating rheumatoid arthritis by administering a combination therapy comprising methotrexate and small molecule alpha-4 integrin antagonist that inhibits the alpha-4 integrin (α4 integrin) interaction with VCAM-1. The invention further relates to methods of preparing the compounds and methods of using the compounds and compositions.

  本申请涉及通过以治疗有效剂量给予甲氨蝶呤和α-4整合素抗体或免疫活性抗原结合片段的联合治疗方法和组合物，治疗类风湿性关节炎。该申请还涉及通过以治疗有效剂量给予甲氨蝶呤和小分子α-4整合素拮抗剂的联合治疗方法和组合物，该拮抗剂抑制α-4整合素（α4整合素）与VCAM-1的相互作用，通常涉及制备化合物的方法和使用化合物和组合物的方法。
• CARBAMYLOXY COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4
  申请人：Elan Pharmaceuticals, Inc.

  公开号：EP1000051A1

  公开（公告）日：2000-05-17